108 related articles for article (PubMed ID: 33964573)
1. Circulating Epstein-Barr virus DNA level post induction chemotherapy contributes to prognostication in advanced-stage nasopharyngeal carcinoma.
Chen FP; Luo YS; Chen K; Li JY; Huo LQ; Shi L; Ou-Yang Y; Cao XP
Eur J Cancer; 2021 Jul; 151():63-71. PubMed ID: 33964573
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of adding PD-1 blockade to induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) for locoregionally advanced nasopharyngeal carcinoma: an observational, propensity score-matched analysis.
Jin YN; Qiang MY; Wang Y; Lin YJ; Jiang RW; Cao WW; Zhang WJ; Wang SY; Zhang HY; Yao JJ
Cancer Immunol Immunother; 2024 May; 73(7):125. PubMed ID: 38733402
[TBL] [Abstract][Full Text] [Related]
3. Dynamic changes in plasma Epstein-Barr virus DNA load during treatment have prognostic value in nasopharyngeal carcinoma: a retrospective study.
He SS; Wang Y; Bao Y; Cai XY; Yang XL; Chen DM; Chen Y; Lu LX
Cancer Med; 2018 Apr; 7(4):1110-1117. PubMed ID: 29493874
[TBL] [Abstract][Full Text] [Related]
4. Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients receiving additional induction chemotherapy.
Lv JW; Qi ZY; Zhou GQ; He XJ; Chen YP; Mao YP; Chen L; Tang LL; Li WF; Lin AH; Ma J; Sun Y
Cancer Sci; 2018 Mar; 109(3):751-763. PubMed ID: 29266526
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a novel model incorporating serological indicators into the conventional TNM staging system for nasopharyngeal carcinoma.
Ding C; Dai DY; Luo ZK; Wang GY; Dong Z; Qin GJ; Du XJ; Ma J
Oral Oncol; 2024 Apr; 151():106725. PubMed ID: 38430711
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients: a systematic review and meta-analysis.
Wang BC; Xiao BY; Lin GH; Wang C; Liu Q
BMC Cancer; 2020 May; 20(1):393. PubMed ID: 32375701
[TBL] [Abstract][Full Text] [Related]
7. A nomogram based on nutritional and inflammatory parameters to predict DMFS and identify beneficiaries of adjuvant chemotherapy in IVA-stage nasopharyngeal carcinoma.
Pan Y; Chen Z; Hong W; Huang Z; Li Y; Cai S; Lai J; Lu J; Qiu S
BMC Cancer; 2024 May; 24(1):578. PubMed ID: 38734620
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: Defining high-risk patients who may benefit before concurrent chemotherapy combined with intensity-modulated radiotherapy.
Du XJ; Tang LL; Chen L; Mao YP; Guo R; Liu X; Sun Y; Zeng MS; Kang TB; Shao JY; Lin AH; Ma J
Sci Rep; 2015 Nov; 5():16664. PubMed ID: 26564805
[TBL] [Abstract][Full Text] [Related]
9. Combination of nivolumab with standard induction chemotherapy in children and adults with EBV-positive nasopharyngeal carcinoma : Protocol of a prospective multicenter phase 2 trial.
Römer T; Vokuhl C; Staatz G; Mottaghy FM; Christiansen H; Eble MJ; Timmermann B; Klussmann JP; Elbracht M; Calaminus G; Zimmermann M; Brümmendorf TH; Feuchtinger T; Kerp H; Kontny U
HNO; 2024 Jun; 72(6):423-439. PubMed ID: 38214716
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin-docetaxel induction chemotherapy for patients with nasopharyngeal carcinoma in a non-endemic cohort.
Özkaya Toraman K; Meral R; Karadeniz AN; Kaval G; Başaran M; Ekenel M; Altun M
J Chemother; 2024 Apr; 36(2):133-142. PubMed ID: 37211862
[TBL] [Abstract][Full Text] [Related]
11. Induction chemotherapy regimes in first-line treatment for locoregionally advanced nasopharyngeal carcinoma: A network meta-analysis and cost-effectiveness analysis.
Xu W; Qiu L; Li F; Fei Y; Wei Q; Shi K; Zhu Y; Luo J; Wu M; Yuan J; Liu H; Mao J; Cao Y; Zhou S; Guan X
Oral Oncol; 2024 Jul; 154():106865. PubMed ID: 38823173
[TBL] [Abstract][Full Text] [Related]
12. Effect of waiting time for radiotherapy after last induction chemotherapy on prognosis of locally advanced nasopharyngeal carcinoma.
Zhu KX; Ding T; E YM; Yang HW; Wu RP; Liu RJ; Zhou LL; Fu WJ; Jiang MP; Wang XL
Head Neck; 2024 May; 46(5):1189-1200. PubMed ID: 38366691
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy.
Lechner M; Schartinger VH; Steele CD; Nei WL; Ooft ML; Schreiber LM; Pipinikas CP; Chung GT; Chan YY; Wu F; To KF; Tsang CM; Pearce W; Morelli D; Philpott M; Masterson L; Nibhani R; Wells G; Bell CG; Koller J; Delecluse S; Yip YL; Liu J; Forde CT; Forster MD; Jay A; Dudás J; Krapp A; Wan S; Uprimny C; Sprung S; Haybaeck J; Fenton TR; Chester K; Thirlwell C; Royle G; Marafioti T; Gupta R; Indrasari SR; Herdini C; Slim MAM; Indrawati I; Sutton L; Fles R; Tan B; Yeong J; Jain A; Han S; Wang H; Loke KSH; He W; Xu R; Jin H; Cheng Z; Howard D; Hwang PH; Le QT; Tay JK; West RB; Tsao SW; Meyer T; Riechelmann H; Oppermann U; Delecluse HJ; Willems SM; Chua MLK; Busson P; Lo KW; Wollmann G; Pillay N; Vanhaesebroeck B; Lund VJ
Nat Commun; 2021 Jan; 12(1):117. PubMed ID: 33402692
[TBL] [Abstract][Full Text] [Related]
14. Early Stage and Locally Advanced Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Going?
Juarez-Vignon Whaley JJ; Afkhami M; Sampath S; Amini A; Bell D; Villaflor VM
Curr Treat Options Oncol; 2023 Jul; 24(7):845-866. PubMed ID: 37145382
[TBL] [Abstract][Full Text] [Related]
15. Predictive progression outcomes and risk stratification in patients with recurrent or metastatic nasopharyngeal carcinoma who received first-line immunochemotherapy.
He D; Zhang Y; He S; Zhang Y; Dai K; Xu C; Huang Y
Clin Transl Oncol; 2024 May; 26(5):1209-1219. PubMed ID: 38070050
[TBL] [Abstract][Full Text] [Related]
16. Progesterone analogues reduce plasma Epstein-Barr virus DNA load and improve pain control in recurrent/metastatic nasopharyngeal carcinoma patients under supportive care.
Hung CY; Lin TL; Kuo YC; Hsieh CH; Wang HM; Hsu CL
Biomed J; 2017 Aug; 40(4):212-218. PubMed ID: 28918909
[TBL] [Abstract][Full Text] [Related]
17. Incorporation of PD-1 blockade into induction chemotherapy improved tumor response in patients with locoregionally advanced nasopharyngeal carcinoma in a retrospective patient cohort.
Yao Y; Ouyang Q; Wang S; Li K; Luo Q; Qiu L; Liu F; Tan L; Li Q; Ren B; Long P; Ye J; Zhong X
Oral Oncol; 2024 Jul; 154():106867. PubMed ID: 38797001
[TBL] [Abstract][Full Text] [Related]
18. Effect of immune-modulating metronomic capecitabine as an adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma.
He Q; Luo X; Liu L; Zhao C; Li Z; Jin F
BMC Immunol; 2024 May; 25(1):28. PubMed ID: 38710996
[TBL] [Abstract][Full Text] [Related]
19. Prognostic model for risk stratification of de novo metastatic nasopharyngeal carcinoma patients treated with chemotherapy followed by locoregional radiotherapy.
Li WZ; Hua X; Xie DH; Liang H; Liu GY; Xia WX; Xiang YQ
ESMO Open; 2021 Feb; 6(1):100004. PubMed ID: 33399071
[TBL] [Abstract][Full Text] [Related]
20. VLDL and LDL Subfractions Enhance the Risk Stratification of Individuals Who Underwent Epstein-Barr Virus-Based Screening for Nasopharyngeal Carcinoma: A Multicenter Cohort Study.
Zhou Z; Tang T; Li N; Zheng Q; Xiao T; Tian Y; Sun J; Zhang L; Wang X; Wang Y; Ye F; Chen Z; Zhang H; Zheng X; Cai Z; Liu L; Guan J
Adv Sci (Weinh); 2024 Jun; 11(22):e2308765. PubMed ID: 38520712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
